Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile
Stocks in this Quantisnow insightHealth Care
Historical context for BHVN
Across the 17 sessions after earlier BHVN headlines, the stock closed higher 11 times and lower 6 times, with a median move of 5.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | BHVN | SPY |
|---|---|---|---|
| May 5, 2026 | Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results | -4.2% | +0.8% |
| Apr 13, 2026 | Canaccord Genuity initiated coverage on Biohaven with a new price target | +10.4% | +1.0% |
| Mar 19, 2026 | Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment | -1.4% | -0.2% |
| Mar 3, 2026 | Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results | -9.7% | -0.9% |
| Feb 6, 2026 | Goldman initiated coverage on Biohaven with a new price target | +7.8% | +1.9% |
| Jan 21, 2026 | Biohaven upgraded by RBC Capital Mkts with a new price target | +1.5% | +1.2% |
Keep researching BHVN
Quantisnow market dataNYSE
BHVN
Biohaven Ltd.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2022
Get push alerts for BHVN
Full BHVN profile on Quantisnow Follow BHVN and get a push notification the moment its next story breaks.